非神经毁损性奇神经节阻滞治疗尾骨痛及相关疾病:系统综述与荟萃分析
荟萃分析含11项研究391例患者,基线疼痛评分7.93(95%CI 7.81–8.04),GIB在短期(≤3个月)、中期(3–6个月)和长期(>6个月)均显著降低疼痛,标准化均数差分别为-2.73、-2.13、-1.86,未见严重不良事件,但证据确定性极低。
要点
- 非神经毁损性GIB可显著降低慢性尾骨痛,短期至长期随访均有效。
- 未报告严重不良事件,提示该干预可能安全。
- 证据确定性为极低,临床决策需结合个体情况。
核心结论
- 非神经毁损性奇神经节阻滞可能对慢性难治性尾骨痛安全且有效。
研究设计与样本
- 系统综述与荟萃分析,遵循PRISMA指南,检索PubMed、Embase、CINAHL和Web of Science(2024年2月)。
- 采用标准化均数差(SMD)在0–10量表上进行合并分析。
主要发现
- 所有研究均报告GIB后疼痛有不同程度改善。
- 荟萃分析纳入患者的基线疼痛评分为7.93(95%CI 7.81–8.04)。
- GIB在3个月时SMD为-2.73(95%CI -3.45至-2.01),3–6个月为-2.13(95%CI -2.82至-1.45),>6个月为-1.86(95%CI -2.58至-1.15)。
- 未见严重不良事件报告。
- GRADE评估显示所有结局的证据确定性均为极低。
临床怎么用
- 对保守治疗失败的慢性尾骨痛患者,可考虑非神经毁损性GIB作为微创干预选项。
- 临床应用中需告知患者证据确定性极低,疗效与安全性需进一步验证。
局限性
- 所有结局的证据确定性均为极低(GRADE评估)。
- 研究间存在异质性,且部分研究样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/IMPORTANCE: Chronic coccydynia is a challenging condition to manage. Conflicting evidence exists regarding the role of the ganglion impar in coccygeal nociception. When conservative treatments fail, minimally invasive interventions at the ganglion impar may be effective in providing relief. OBJECTIVES: To evaluate the effectiveness and safety of ganglion impar blocks (GIBs) for the management of chronic coccydynia. EVIDENCE REVIEW: A systematic review and meta-analysis was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Relevant studies were identified through a comprehensive literature search of PubMed, Embase Classic+ Embase, CINAHL and the Web of Science in February 2024. Data on patient characteristics, intervention details, pain outcomes (measured by Visual Analog Scale and Numerical Pain Rating Scale) and adverse events were extracted. Meta-analysis was performed using standardized mean differences (SMDs) on scale of 0 to 10. FINDINGS: Seventeen studies described 625 coccydynia patients treated with GIB. All studies reported some level of improvement of pain after GIB. The meta-analysis included 11 studies totaling 391 patients with a baseline pain score of 7.93 (7.81 to 8.04 95% CI). GIBs were effective in reducing coccygeal pain at short-term (up to 3 months), intermediate-term (3-6 months) and long-term (greater than 6 months) follow-up. SMDs were -2.73 (95% CI -3.45 to -2.01), -2.13 (95% CI -2.82 to -1.45), -1.86 (95% CI -2.58 to -1.15) at 3 months, 3-6 months and >6 months, respectively. No serious adverse events were noted. Grading of Recommendations Assessment, Development and Evaluation assessment indicated 'very low' certainty of evidence across all outcomes. CONCLUSIONS: Non-neurodestructive GIB may be a safe and potentially effective treatment option for patients with chronic, refractory coccydynia. PROSPERO REGISTRATION NUMBER: CRD42024506056.
引用
- Jevotovsky DS, Chopra H, Pak DJ, et al. Non-neurodestructive ganglion impar blocks for coccydynia and related disorders: a systematic review and meta-analysis. Reg Anesth Pain Med. 2026. PMID: 40081927. doi:10.1136/rapm-2024-106055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。